Literature DB >> 31423694

Cardiovascular safety of macrolide and fluoroquinolone antibiotics: An analysis of the WHO database of adverse drug reactions.

Giulia Bonaldo1, Luisa Anna Andriani1, Ottavio D'Annibali1, Domenico Motola1, Alberto Vaccheri1.   

Abstract

INTRODUCTION: The cardiovascular safety profile of macrolides and fluoroquinolones has been widely discussed. The aim of the present study is to provide the contribution of real-world data onto the ongoing discussion about cardiovascular toxicity of both macrolides and fluoroquinolones.
METHODS: Reports of adverse drug reactions (ADRs) were retrieved from VigiBase. Macrolides and fluoroquinolones were compared with amoxicillin by using the reporting odds ratio (ROR) as a measure of disproportionality. Macrolides were then compared with fluoroquinolones.
RESULTS: Overall, 6810 reports of ADRs were retrieved: 62% of them were serious and 35% concerned female. Macrolides were more frequently associated with "atrial fibrillation" (ROR = 1.26, CI 1.02-1.57) and "ventricular fibrillation" ROR = 2.60, CI 1.92-3.54) than fluoroquinolones. Antimicrobials more frequently reported for "cardiac disorder" were azithromycin (375 reports) and clarithromycin (302) for macrolides and levofloxacin (470) and moxifloxacin (391) for fluoroquinolones.
CONCLUSION: Our data highlighted that macrolides and fluoroquinolones may influence cardiac rhythm and suggest caution in the prescribing of these drugs to patients with hidden cardiovascular risk factors. Although these ADRs seem to be not common, they have a notable impact in clinical practice because of the huge number of the exposed subjects.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  VigiBase; antibiotics; cardiovascular risk; pharmacovigilance; safety profile

Mesh:

Substances:

Year:  2019        PMID: 31423694     DOI: 10.1002/pds.4873

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  3 in total

1.  The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia.

Authors:  Wenxian Wang; Xiaodong Gu; Lan Shao; Zhiyong Shi; Guangyuan Lou; Zhengbo Song; Yiping Zhang
Journal:  Contrast Media Mol Imaging       Date:  2022-07-14       Impact factor: 3.009

2.  Study of the indications for macrolide prescriptions in a Colombian population

Authors:  Luis Fernando Valladales-Restrepo; Camilo Alexander Constain-Mosquera; María Alejandra Hoyos-Guapacha; Karol Liceth Hoyos-Guapacha; Andrés Gaviria-Mendoza; Manuel Enrique Machado-Duque; Jorge Enrique Machado-Alba
Journal:  Biomedica       Date:  2022-06-01       Impact factor: 1.173

Review 3.  Overview of the Clinical and Molecular Features of Legionella Pneumophila: Focus on Novel Surveillance and Diagnostic Strategies.

Authors:  Giuseppe Gattuso; Roberta Rizzo; Alessandro Lavoro; Vincenzoleo Spoto; Giuseppe Porciello; Concetta Montagnese; Diana Cinà; Alessia Cosentino; Cinzia Lombardo; Maria Lina Mezzatesta; Mario Salmeri
Journal:  Antibiotics (Basel)       Date:  2022-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.